Source: Eur Respir J 2016; 48: 938-943
Disease area: Paediatric lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Tadolini Marina, Garcia-Prats Anthony J., D'Ambrosio Lia, Hewison Catherine, Centis Rosella, Schaaf H. Simon, Marais Ben J., Ferreira Hannetjie, Caminero Jose A., Jonckheere Sylvie, Sinha Animesh, Herboczek Krzysztof, Khaidarkhanova Zarema, Hayrapetyan Armen, Khachatryan Naira, Urtkmelidze Ia, Loreti Carolina, Esposito Susanna, Matteelli Alberto, Furin Jennifer, Varaine Francis, Migliori Giovanni Battista. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. Eur Respir J 2016; 48: 938-943

Member's Comments

No comment yet.

Related content which might interest you: Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives Source: Eur Respir Rev, 28 (152) 190035; 10.1183/16000617.0035-2019 Year: 2019 New and repurposed TB drugs use in children and adolescents with M/XDR-TB Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now? Year: 2017 Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis? Source: Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019 Year: 2020 ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use Source: Eur Respir J 2014; 44: 811-815 Year: 2014 Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update Source: Eur Respir J, 57 (5) 2002483; 10.1183/13993003.02483-2020 Year: 2021 Treatment outcomes among childhood extensively drug-resistant tuberculosis patients in Pakistan Source: ERJ Open Res, 8 (1) 00551-2021; 10.1183/23120541.00551-2021 Year: 2022 HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Treatment options for patients with multidrug-resistant or extensively drug-resistant tuberculosis Source: Annual Congress 2009 - Priorities in tuberculosis research Year: 2009 Two major problems in TB patients today: MDR and the abandoned therapy Source: Annual Congress 2011 - Challenges in tuberculosis control Year: 2011 Effectiveness of treatment for MDR TB in children and adolescents Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 A new era for treatment of drug-resistant tuberculosis Source: Eur Respir J, 52 (4) 1801350; 10.1183/13993003.01350-2018 Year: 2018 Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013 Multidrug- and extensively drug-resistant tuberculosis: an emerging threat Source: Eur Respir Rev 2009; 18: 195-197 Year: 2009 Clinical outcomes of patients with drug-resistant and extensively drug-resistant tuberculosis in Europe Source: Annual Congress 2008 - Priorities for tuberculosis research in Europe: discussing the results of the Tuberculosis Network European Trials Group (TBNET) Year: 2008 Psychiatric issues during the treatment of the patients with multidrug-resistant tuberculosis Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Management of drug resistant pulmonary TB. New problems and perspectives Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis Year: 2009 The comparative analysis of treatment effectiveness in children and adolescents with MDR TB with anti-TB drugs of the first and second lines Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012 Managing adult and children XDR-TB cases with limited clinical options Source: International Congress 2018 – CC4 Tuberculosis Year: 2018 Medico-social features of resistance development to new anti–TB drugs in patients with MDR/XDR TB Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021